The portfolio will be offered to low- and lower-middle-income countries to help financially strained healthcare systems care for COVID-19 patients.
List view / Grid view
Filter the results
The FDA has given the designation to niraparib for the treatment of gene-mutated castration-resistant prostate cancer.
The EC has granted approval to broaden the existing marketing authorisation for Zytiga to include early stage metastatic prostate cancer...